Hold your horses! For the kinds of FoB’s MNTA is likely to be interested in—e.g. mAbs—limited clinical trials probably will be required, at least initially. The FDA’s waiving of clinical trials is most likely for the relatively simple proteins such as the interferons, ESA’s, and variants of G-CSF.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.